American Society of Hematology

Figure 4.

$Characterization of G-Rex-expanded TCR/CD3-depleted CAR T-cell products. (A) Experimental setup for nonviral TRAC integration of CD19-CAR into primary human T cells and subsequent CAR4 NK-92 cell–mediated depletion of residual TCR-unedited cells. (B-E) Product characteristics on day 14 after T-cell isolation: (B) residual TCR/CD3+ (wild-type) T-cell fraction (unpurified refers to the condition previously termed as T cells only); (C) normalized total cell counts; (D) CD8:CD4 ratios; and (E) TCRα/β:TCR γ/δ ratios within residual CD3+ T-cell fractions. (F) 6 hour VITAL assay to assess the target-specific cytotoxicity of differently purified CD19-CAR T cells. (G) Intracellular cytokine expression assay to assess the effector function of CD19-CAR T cells after CD19+ target cell encounters. mock-E, mock-electroporated wild-type T-cell controls.$

Characterization of G-Rex-expanded TCR/CD3-depleted CAR T-cell products. (A) Experimental setup for nonviral TRAC integration of CD19-CAR into primary human T cells and subsequent CAR4 NK-92 cell–mediated depletion of residual TCR-unedited cells. (B-E) Product characteristics on day 14 after T-cell isolation: (B) residual TCR/CD3⁺ (wild-type) T-cell fraction (unpurified refers to the condition previously termed as T cells only); (C) normalized total cell counts; (D) CD8:CD4 ratios; and (E) TCRα/β:TCR γ/δ ratios within residual CD3⁺ T-cell fractions. (F) 6 hour VITAL assay to assess the target-specific cytotoxicity of differently purified CD19-CAR T cells. (G) Intracellular cytokine expression assay to assess the effector function of CD19-CAR T cells after CD19⁺ target cell encounters. mock-E, mock-electroporated wild-type T-cell controls.

This Feature Is Available To Subscribers Only